Luke Fracek

Osteoarthritis (OA) remains a challenging disease due to the increased rate of incidence in the older population and the lack of a disease-modifying drug. BMP signaling plays a crucial role in chondrogenic differentiation and in the stability of articular cartilage. However, because BMP-2 also induces chondrocyte hypertrophy, it is not a viable drug for OA treatment. In contrast, the Bmpr1a biomimetic peptide can repair articular cartilage without inducing chondrocyte hypertrophy in the OA mouse model and in chondrocytes derived from patients diagnosed with OA. Despite this benefit, the mechanism by which the peptide drives chondrogenesis remains elusive. To explore this, we use a phosphoproteomics approach to identify pathways differentially activated by CK2.1. Specifically, we identified differentially phosphorylated phosphosites by CK2.1. Based on these phosphosites that we identified, we propose a molecular mechanism by which CK2.1 activates chondrogenesis. Notably, we predict that the mitogen-activated protein kinase (MAPK) pathway is regulated by CK2.1 to induce proteoglycan synthesis in C3H10T1/2 cells.

Bone marrow-derived mesenchymal stem cells (BMSCs), owing to their osteoblastogenic differentiation potential, are crucial for maintaining bone homeostasis and remodeling. Nevertheless, in aging and age-related bone diseases like osteoporosis, BMSCs show significantly diminished osteogenic potential, with a concomitant increase in adipogenic differentiation. The aged BMSCs also become desensitized to BMP2 stimulation to a large extent and exhibit aberrations in BMP2 signaling. However, the molecular mechanisms facilitating this shift in lineage commitment and mediating the cellular dysfunctions remain elusive. This knowledge gap hinders the development of regenerative strategies for skeletal aging and osteoporosis. This study employed an integrative tandem mass tag (TMT)-based phosphoproteomic and total proteomic profiling on BMSCs isolated from young (6-month) and aged (15-month) C57BL/6 (B6) mice to elucidate global alterations in both protein activity and expression. The analysis identified more than 500 proteins that underwent significant alterations (BH-adjusted p-value < 0.05) either in phosphorylation or expression between young and aged BMSCs. Many lineage-specific markers also underwent changes in both phosphorylation and expression with aging. Additionally, key biological processes, including cellular metabolism, clathrin-mediated endocytosis, and nucleocytoplasmic transport mechanisms, were enriched for the deregulated proteins. Signaling proteins, ERK-1/2, had increased activating phosphorylation in the aged BMSCs, while transcription factors Lrrfip1, Ruvbl1, and Ruvbl2 also exhibited dysregulated activity and abundance in the aged BMSCs. The findings from the study adds significant mechanistic insights into how aging disrupts signal transduction, metabolism, and transcriptional program in BMSCs, contributing to age-associated loss of bone mass and reduced skeletal regenerative capabilities. Through the identification of key mediators of BMSC dysfunction seen in aging, this work offers a strong foundation in devising potential therapeutic strategies to restore diminished osteogenic potential and treat osteoporosis.

Osteoarthritis (OA) is a common and debilitating degenerative joint disease associated with aging and more common among women. OA is a disease that affects many parts of the joint, including cartilage, subchondral bone, and the synovium. Although the exact cause of OA is still under investigation, major factors include dysregulation of inflammatory cytokines and loss of function of mesenchymal stem cells (MSCs). Unfortunately, current treatments for OA are limited to symptomatic management, including nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular injections such as hyaluronic acid (or cortisol), physical therapy, and surgical intervention, none of which can affect disease progression or provide permanent solutions. Currently there is no FDA approved treatment that can address the molecular basis of OA, although some promising candidates include bone marrow-derived MSC injection, adipose-derived MSC injection, pulsed electromagnetic field (PEMF), TissueGene-C, and CK2.1.